Bliss GVS Pharma Ltd
NSE:BLISSGVS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sasbadi Holdings Bhd
KLSE:SASBADI
|
MY |
|
M
|
Mestron Holdings Bhd
KLSE:MESTRON
|
MY |
|
I
|
Inner Mongolia BaoTou Steel Union Co Ltd
SSE:600010
|
CN |
|
SMA Solar Technology AG
LSE:0NIF
|
DE |
|
G
|
Gerdau SA
NYSE:GGB
|
BR |
|
Pranavaditya Spinning Mills Ltd
BSE:531172
|
IN |
|
C
|
Concord Acquisition II Corp
AMEX:CNDA
|
US |
|
H
|
Hangzhou Changchuan Technology Co Ltd
SZSE:300604
|
CN |
|
Kesko Oyj
OMXH:KESKOB
|
FI |
|
Shibaura Mechatronics Corp
TSE:6590
|
JP |
|
Ministop Co Ltd
TSE:9946
|
JP |
|
J
|
Jinke Property Group Co Ltd
SZSE:000656
|
CN |
|
Suse SA
XETRA:SUSE
|
LU |
|
SY Holdings Group Ltd
HKEX:6069
|
CN |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IN |
|
Bliss GVS Pharma Ltd
NSE:BLISSGVS
|
27.4B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
563.9B USD |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
234.5B GBP |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
225.3B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.7B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
156.7B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121.1B USD |
Loading...
|
Market Distribution
| Min | -3 052.3% |
| 30th Percentile | 26.9% |
| Median | 39% |
| 70th Percentile | 53.3% |
| Max | 8 269.1% |
Other Profitability Ratios
Bliss GVS Pharma Ltd
Glance View
Bliss GVS Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations. The company is headquartered in Mumbai, Maharashtra and currently employs 750 full-time employees. The company went IPO on 2010-07-26. The firm offers a range of suppositories, tablets, suspensions and injections to various therapeutic segments, including antimalarial, antifungal, dermatological, contraceptive, laxative, anti-hemorrhoidal, antispasmodic, antibiotic, antimicrobial antipyretic, analgesic and anti-inflammatory. The firm's pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, soft gelatin capsules and syrups. its other healthcare products include balm, nasal inhaler, solution, soap, vaginal wash, roll on, shampoo, powder, spray and petroleum jelly. The firm offers its products under various brands, which include Lonart, Funbact, P-Alaxin, Lofnac, Amoxicillin, Antiderm Extra Plus and Esmazole. Its product portfolio comprises over 250 branded formulations across 20 therapeutic segments.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Bliss GVS Pharma Ltd is 52.7%, which is above its 3-year median of 49%.
Over the last 3 years, Bliss GVS Pharma Ltd’s Gross Margin has increased from 48.3% to 52.7%. During this period, it reached a low of 45.7% on Mar 31, 2023 and a high of 52.7% on Jan 1, 2026.
